Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation


Gilead to License Special Around the world Legal rights to the Investigational Applicant DF7001, a 5T4-Targeting NK Mobile Engager for Stable Tumors

Gilead to Have Solutions to License Several Extra NK Cell Engager Systems

FOSTER Town, Calif. & WALTHAM, Mass., May possibly 02, 2022–(Business enterprise WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics now announced a collaboration created to progress a range of Dragonfly’s novel all-natural killer (NK) cell engager-based mostly immunotherapies for oncology and inflammation indications. NK mobile engagers depict a novel system with the opportunity to deal with a broad assortment of cancers, together with potential for action in checkpoint resistant and refractory tumors, as properly as other disease locations these kinds of as irritation. Less than the arrangement, Gilead will get an exceptional, around the globe license from Dragonfly for the 5T4-focusing on investigational immunotherapy software, DF7001. The settlement also grants Gilead possibilities, soon after the completion of specific preclinical activities, to license unique, worldwide rights to create and commercialize more NK cell engager programs using the Dragonfly Tri-precise NK Engager (TriNKET™) platform. TriNKETs are activators of the innate and adaptive immune programs, recruiting NK and cytotoxic T cells into the tumor microenvironment.

This press release options multimedia. Check out the full release in this article:

DF7001 is a TriNKET developed to activate and immediate NK and cytotoxic T mobile killing towards most cancers cells. The goal of DF7001 is 5T4, a protein expressed on most cancers cells and stromal cells that assistance tumor expansion connected with poor prognosis in a number of cancers, which includes non-little cell lung most cancers (NSCLC), pancreatic cancer, breast most cancers, and head and neck squamous mobile carcinomas (HNSCC). DF7001 has the potential to cause the killing of 5T4+ expressing cells, including tumor cells, cancer-affiliated fibroblasts and most cancers stem cells. The software is on observe for submitting an Investigational New Drug (IND) application in the very first fifty percent of 2023.

“We are energized to partner with Dragonfly as we broaden our pipeline with impressive NK mobile engager plans. Applying our scientific framework to focus our efforts, we are increasing our portfolio with belongings that have complementary MOAs and sturdy scientific rationale for mix prospects,” said Flavius Martin, MD, Executive Vice President, Study at Gilead. “We seem forward to operating with the Dragonfly team to take a look at novel NK engager therapies across numerous therapeutic locations to handle some of the biggest gaps in treatment for cancer and inflammatory conditions.”

“Gilead’s expense in Dragonfly, and especially in DF7001, reinforces the worth of our TriNKET system and the differentiated and sustainable technique centered on people with cancer and inflammatory diseases,” reported Monthly bill Haney, Co-Founder and Main Executive Officer of Dragonfly. “Gilead has a effectively-recognized keep track of file in growth and commercialization and is a nicely-matched lover for our scientific experience and system. We glimpse ahead to operating with the Gilead staff to advance new cure choices where by there is a substantial unmet want.”

Terms of the Settlement

Less than the phrases of the arrangement, Gilead will make a $300 million upfront payment to Dragonfly. In addition, Dragonfly is suitable to get opportunity decide-in payments and overall performance-centered enhancement, regulatory and business milestone payments. Dragonfly will also be suitable to obtain royalties of up to 20% on around the world net profits.

The transaction is subject matter to clearance underneath the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

DF7001 is an investigational merchandise prospect it is not permitted by any regulatory company for any use and has not been tested secure or efficacious.

About Dragonfly

Dragonfly Therapeutics, Inc. is a medical-stage biopharmaceutical business fully commited to identifying, producing and commercializing therapies that use its novel TriNKET™ technological know-how to harness the body’s innate immune technique to carry breakthrough therapies to individuals.

For additional details take a look at:

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical firm that has pursued and realized breakthroughs in drugs for a lot more than three a long time, with the intention of creating a healthier world for all folks. The company is committed to advancing ground breaking medications to avoid and handle life-threatening ailments, such as HIV, viral hepatitis, most cancers, and inflammation. Gilead operates in far more than 35 nations globally, with headquarters in Foster Town, California.

Gilead Forward-On the lookout Statements

This push release consists of ahead-hunting statements in the which means of the Non-public Securities Litigation Reform Act of 1995 that are topic to hazards, uncertainties and other things, which includes the capability of the get-togethers to finish the transaction in a timely way or at all the possibility that numerous closing problems for the transaction might not be content or waived, such as the possibility that a governmental entity might prohibit, hold off or refuse to grant approval for the consummation of the transaction the hazard that Gilead may not notice the opportunity added benefits of this collaboration with Dragonfly or other investments in oncology complications or unanticipated bills in connection with the collaboration and the probable results on Gilead’s revenues and earnings the ability of the get-togethers to initiate, development or total scientific trials inside of presently expected timelines or at all, and the possibility of unfavorable benefits from ongoing or extra trials, which includes all those involving DF7001 or any other NK cell engager plan the skill of the events to file applications for regulatory acceptance or receive regulatory approvals in a well timed method or at all, which include individuals involving DF7001 or any other NK cell engager method, and the chance that any these types of approvals may perhaps be topic to sizeable restrictions on use the risk that the events may perhaps make a strategic determination to terminate the collaborations, including the improvement of DF7001 or any other NK cell engager program, at any time and any assumptions underlying any of the foregoing. These and other dangers, uncertainties and other components are explained in element in Gilead’s Yearly Report on Sort 10-K for the year finished December 31, 2021, as submitted with the U.S. Securities and Exchange Fee. These threats, uncertainties and other components could lead to genuine outcomes to vary materially from people referred to in the ahead-seeking statements. All statements other than statements of historic point are statements that could be deemed ahead-seeking statements. The reader is cautioned that any this kind of ahead-looking statements are not ensures of future overall performance and contain dangers and uncertainties, and is cautioned not to position undue reliance on these forward-seeking statements. All forward-on the lookout statements are centered on details at present readily available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such ahead-hunting statements.

Gilead and the Gilead symbol are logos of Gilead Sciences, Inc., or its similar organizations.

For a lot more info about Gilead, make sure you go to the company’s site at, stick to Gilead on Twitter (@GileadSciences) or connect with Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Look at supply edition on


Gilead Contacts:
Jacquie Ross, Investors
[email protected]

Jaisy Wagner Kinds, International Media
[email protected]

Dragonfly Get hold of:
Anne Deconinck, Media
[email protected]


Resource backlink

Natasha M. McKnight

Next Post

SEL Skills for the Game of Life 

Mon May 9 , 2022
[ad_1] Display learners how significantly enjoyable teamwork can be by diving into the professional-social animated earth of LaGolda. Encourage students to embrace collaboration and produce core social-emotional expertise that they can use to maintain their heads in the game—no matter what existence throws their way.  Tackling Challenges Collectively  A sequence […]

You May Like